ZA200801678B - Treatment of inflammatory bowel disease - Google Patents

Treatment of inflammatory bowel disease

Info

Publication number
ZA200801678B
ZA200801678B ZA200801678A ZA200801678A ZA200801678B ZA 200801678 B ZA200801678 B ZA 200801678B ZA 200801678 A ZA200801678 A ZA 200801678A ZA 200801678 A ZA200801678 A ZA 200801678A ZA 200801678 B ZA200801678 B ZA 200801678B
Authority
ZA
South Africa
Prior art keywords
treatment
inflammatory bowel
bowel disease
disease
inflammatory
Prior art date
Application number
ZA200801678A
Other languages
English (en)
Inventor
Winqvist Ola
Thoern Magnus
Original Assignee
Ith Immune Therapy Holdings Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ith Immune Therapy Holdings Ab filed Critical Ith Immune Therapy Holdings Ab
Publication of ZA200801678B publication Critical patent/ZA200801678B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200801678A 2005-08-31 2008-02-20 Treatment of inflammatory bowel disease ZA200801678B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0501916 2005-08-31

Publications (1)

Publication Number Publication Date
ZA200801678B true ZA200801678B (en) 2008-12-31

Family

ID=37809140

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200801678A ZA200801678B (en) 2005-08-31 2008-02-20 Treatment of inflammatory bowel disease

Country Status (13)

Country Link
US (1) US8852581B2 (fr)
EP (1) EP1933854B1 (fr)
JP (1) JP5492414B2 (fr)
KR (1) KR101475800B1 (fr)
CN (1) CN101252941A (fr)
AU (1) AU2006285446B2 (fr)
CA (1) CA2619735C (fr)
EA (1) EA015989B1 (fr)
IL (1) IL189611A (fr)
NO (1) NO341189B1 (fr)
SG (1) SG165328A1 (fr)
WO (1) WO2007027132A1 (fr)
ZA (1) ZA200801678B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015989B1 (ru) 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
EP2062970A1 (fr) 2007-11-26 2009-05-27 Txcell Compositions pour traiter une condition inflammatoire intestinale
CN102732480A (zh) * 2012-06-11 2012-10-17 中山大学 N-乙酰半胱氨酸对中央记忆性t细胞的绝对数量在体外扩增上的应用
WO2014104305A1 (fr) * 2012-12-28 2014-07-03 持田製薬株式会社 Diagnostic de la maladie inflammatoire chronique de l'intestin par la mesure de la présepsine
EP3071686B1 (fr) 2013-11-22 2020-07-22 Cellectis SA Procédé de production de lots de lymphocytes t allogéniques de puissance moyennee
CN103911341B (zh) * 2014-01-26 2016-04-13 山东迪博生物科技股份有限公司 Th1细胞亚群的制备方法及其在制备抗肿瘤细胞制剂中的应用
JP2018188408A (ja) * 2017-05-11 2018-11-29 国立大学法人群馬大学 制御性ｔ細胞増強剤並びにそれを含む医薬及び食品組成物
GB201714777D0 (en) * 2017-09-14 2017-11-01 Univ London Queen Mary Agent
RU2728696C2 (ru) * 2018-12-28 2020-07-30 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Моноклональное антитело к интерферону бета-1а человека
CN110051698A (zh) * 2019-03-18 2019-07-26 天津大学 基于微囊化处理的肠道原生菌基因改造的方法
CN111374989B (zh) * 2020-03-16 2022-04-19 中山大学附属第五医院 用于治疗炎症性肠病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
FR2824567B1 (fr) * 2001-05-11 2003-08-08 Inst Nat Sante Rech Med Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
WO2003059264A2 (fr) 2001-12-21 2003-07-24 University Of Southern California Procedes d'induction de lymphocytes t regulateurs professionnels et des lymphocytes t produisant des cytokines
JP4395070B2 (ja) 2002-06-25 2010-01-06 インデックス・ダイアグノスティックス・アクチエボラーグ 潰瘍性大腸炎を診断するための方法およびキット
ATE353954T1 (de) * 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
WO2004050706A2 (fr) * 2002-12-03 2004-06-17 Medical Research Council Lymphocytes t regulateurs
EP1667669A2 (fr) 2003-05-30 2006-06-14 Molecular Staging, Inc. Maladies intestinales inflammatoires
CA2552891A1 (fr) * 2004-01-08 2005-08-04 Regents Of The University Of California Lymphocytes t regulateurs supprimant l'auto-immunite
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
EA015989B1 (ru) 2005-08-31 2012-01-30 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительного заболевания кишечника
CN101443041A (zh) 2006-05-12 2009-05-27 Ibd柱疗法国际股份公司 治疗炎性肠病的方法和装置
KR20100063052A (ko) 2007-08-02 2010-06-10 아이에스에스 이뮨 시스템 스티뮬레이션 에이비 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법

Also Published As

Publication number Publication date
CN101252941A (zh) 2008-08-27
JP2009506109A (ja) 2009-02-12
EP1933854A4 (fr) 2012-07-25
CA2619735C (fr) 2014-05-27
AU2006285446A1 (en) 2007-03-08
IL189611A (en) 2011-10-31
CA2619735A1 (fr) 2007-03-08
EA015989B1 (ru) 2012-01-30
US8852581B2 (en) 2014-10-07
JP5492414B2 (ja) 2014-05-14
NO20081539L (no) 2008-05-29
EP1933854A1 (fr) 2008-06-25
WO2007027132A1 (fr) 2007-03-08
NO341189B1 (no) 2017-09-04
KR101475800B1 (ko) 2014-12-23
US20090311228A1 (en) 2009-12-17
EP1933854B1 (fr) 2014-06-25
KR20080047579A (ko) 2008-05-29
SG165328A1 (en) 2010-10-28
AU2006285446B2 (en) 2013-08-22
IL189611A0 (en) 2008-06-05
EA200800662A1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
IL189611A0 (en) Treatment of inflammatory bowel disease
ZA200710598B (en) Treatment of inflammatory conditions
EP1920770A4 (fr) Agent thérapeutique contre l'affection abdominale inflammatoire et inhibiteur de la production de tnf- alpha
GB2450974B (en) Treatment of inflammatory bowel disease with cannabinoids
HK1131047A1 (en) Treatment of inflammatory diseases
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
HK1131002A1 (zh) 用於治療或預防炎性腸道疾病的組合物
EP1931390A4 (fr) Compositions et methodes de traitement de maladies auto-immunes
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
HK1100206A1 (en) Supportive treatment of liver disease
GB0700972D0 (en) Treatment of inflammatory disease
EP2099446A4 (fr) Méthode de traitement de la maladie intestinale inflammatoire
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
EP1755635A4 (fr) Traitement d'affection inflammatoire des voies respiratoires
GB0720976D0 (en) Treatment of inflammatory disease
EP2044957A4 (fr) Agent de traitement pour la maladie intestinale inflammatoire
EP2182976A4 (fr) Traitement d'une maladie auto-immune
GB0526394D0 (en) Treatment of inflammatory diseases
IL187323A0 (en) Treatment of inflammatory bowel disease (ibd) with antiangiogenic compounds
GB0623740D0 (en) Treatment of disease
GB0622136D0 (en) Treatment of gastrointestinal diseases
ZA200607681B (en) Treatment of water
GB0411301D0 (en) Treatment of inflammatory disease
GB0622137D0 (en) Treatment of gastrointestinal diseases